# UNITED STATES NUCLEAR REGULATORY COMMISSION

Beta Gamma Nuclear Radiology, Inc. Fajardo, PR

2008001

Docket No. 03035572 License No. 52-25542-01

#### **REPLY TO A NOTICE OF VIOLATION**

On a letter dated April 8, 2008 Beta Gamma Nuclear Radiology Inc. (hereinafter referred to as Beta Gamma) was served notice of violation<sup>1</sup>. This notice of violation states that During an NRC inspection conducted on March 1, 2008, one violation of NRC requirements was identified. The Notice of Violation alleges that on September 14, 2005, and February 19 and 26, 2008, the license administered 5.17, 3.64 and 3.57 millicuries of 1-131 sodium iodide, respectively, without a written directive. Beta Gamma hereby contests such allegation because a written directive was dated and signed by an authorized user before the administration of I-131 sodium iodide<sup>2</sup>. These directives were for follow-up WB I-131 scan doses (approx. 4mCi doses) on these instances the written directives for this cases are placed in one of the two labels sent by the radiopharmacy. For the I-131 therapy doses for hyperthyroidism and thyroid cancer the written directives are placed in a color coded sheet.

After NRC inspection, I was very surprised that the 3 records stated did not have the written directives prior to dose administration; since the office procedure is that I am present in all the I-131 doses above 30uCi and that the written directives are written before dose administration, and to confirm that the right

<sup>&</sup>lt;sup>1</sup> Docket Number 03035572

<sup>&</sup>lt;sup>2</sup> See attachments "A", "B" and "C". (Please do not place in the Public Document Room nor in the internet due to HIPAA concerns.)

patient is identified by more than one method of identification, that the pregnancy test results are negative, in the appropriate cases, insuring that the full checklist<sup>3</sup> is completed before administering the doses. Therefore, after NRC visit I checked in several places including the patient's record and the daily archive of the radiopharmacy doses for those particular days, to see if the corresponding written directives could have been misplaced there. After checking the daily archives I found the 3 written directives of the mentioned cases<sup>4</sup>. Therefore for these 3 cases there were written directives before I-131 administration; however, the 2 slips enclosed by the radiopharmacy, the one supposed to be archived ended in the record and the one with the written directive on it<sup>5</sup>, ended in the daily archive.

To prevent from this happening again, the written directives for all dosages greater than 30uCi of I-131 sodium iodide will be placed in a color coded form as it has been Beta Gamma standard operation for I-131 therapy doses for hyperthyroidism and thyroid cancer. This corrective step will ensure that the I-131 written directives are not misplaced and more readily accessible during inspection of records. This policy has been informed and discussed with the nuclear medicine technologist and secretary and implemented since April 22, 2008<sup>6</sup>.

In view of the above Beta Gamma respectfully requests the dismissal of the above mentioned notice of violation.

<sup>&</sup>lt;sup>3</sup> In attachment "D".

<sup>&</sup>lt;sup>4</sup> See attachments "A", "B" and "C". (Please do not place in the Public Document Room nor in the internet due to HIPAA concerns.)

<sup>&</sup>lt;sup>5</sup> That was supposed to be placed in the record.

<sup>&</sup>lt;sup>6</sup> See attachment "E".

Under oath I, Juan E. Pérez-Monté declare that I have personal knowledge of all the facts stated on the present reply to the notice of violation and that those facts are true.

In San Juan, Puerto Rico, today May 5, 2008.

from G. Por Mate UAN E. PEREZ-MONTE, M.D.

Affidavit Number: 2818


Suscribed and Sworn before me by Juan E. Pérez-Monté, of legal age, Medical Director of Beta Gamma Nuclear Radiology, Inc. married, resident of Guaynabo, Puerto Rico whom I personally know.

In San Juan, Puerto Rico, today May 5, 2008.

NØTARY PUBLIC



**I HERE BY CERTIFY** that on this same day, I notified via certified mail the U.S. Nuclear Regulatory Commission, ATTN: Document Control Desk, Washington, D.C. 20555, U.S. Nuclear Regulatory Commission Region I 475 Allendale Road King of Prussia, Pennsylvania 19406-1415 and to Director, Office of Enforcement, U.S. Nuclear Regulatory Commission, Washington, DC 20555-0001.



Attachment - A

1-131	NAI THERAPY CAP.	4 MCI 30942
- Latras	THYROID THERAPY 4.00 mCl	@ 12:00 19 Feb 2008 (Tus)
	1.00 CAP	Existence
-	4.00 mCVCAP	12:00 26 Feb 2008 (Tue)
BETA	GAMMA NUCLEAR	. 9 1
FANNOO,		Proved PEREZ MONTE
	DUARDO DIAZ (EDM) 07/4	TO ALL TO MAN
78776555 150 FEDE	RICO COSTAS SHI	bymli 11:20 at

	4207-1
1-131 NAI THERAPY CAP 4	WICI C
4.00 mCl	@ 12:00 25 Feb 2008 (Tue)
4.00 CAP	12:00 04 Mar 2008 (Tuo)
SETA GAMMA NUCLEAR	ALM 9 ALM 1
PALADO MOLINA STE 101 3,57 Mg	RESEZ MONTE
RPh : FOLIARDO DIAZ (FDM) 07460	appling and the second
BINS RADIOPHARMACEUTICA 7877665508 180 FEDERICO COSTAS BAL SAN JUAN PR 00018-1303	57mg 2:0070

Attachment - C



1.0

Attachment - B

#### BETA GAMMA NUCLEAR RADIOLOGY CHECK FOR QUALITY ASSURANCE For use patients receiving more than 30uCi of I-131

Attachment - D

NAN	ЛЕ:				
DAT	`E:	LAB#	ŧ		
		YES	NO	N/A	INICIAI
I.	Written order from the referring physician				
	A. Date		<u> </u>		
	B. History and diagnosis	. <u></u>	<u> </u>		
	C. Signature of referring physician	<u> </u>			
11.	Written directive from authorized user physician				
	A. Date of treatment				
	B. Type of treatment				
	C. Radiopharmaceutical		<u> </u>	N.	
	D. Dosage	<u> </u>			· · · · · · · · · · · · · · · · · · ·
	E. Route of administration				
	F. Signature of authorized user-physician	·			
III.	Patient identify				
111.	A. Patient's name asked				
	B. Compared with name in ID bracelet	<del></del>			
	C. Compared with name in its ordected				
	information				
	1. birth date				
	2. address	<del></del>			
	3. social security number				
	4. signature				
	4. signature		<u></u>		
IV.	Verify written directive before administering				
	radiopharmaceutical				
	A. Radiopharmaceutical				
	B. Dosage (measured in dose CAL)				
	C. Route of administration				
v.	Evidence patient record				
••	A. Date				
	B. Time				
	C. Radiopharmaceutical				
	D. Volume				·
	E. Route of administration	<u> </u>			
	F. Pregnancy test (if applicable)			<u> </u>	
VI.	Signature of patient in "Permiso para uso de				
¥ I.	radioisotopo"				
	rauoisolopo				

VII. Signature of authorized person who administered the radiopharmaceutical

SIGNATURE

### Beta Gamma Nuclear Radiology, Inc. PMB 372 PO BOX 7891 Guaynabo PR 00970

Attacment -E

April 22, 2008

To: All Nuclear Medicine Personnel

SDC

From: Juan E. Pérez Monté, M.D.

## RE: Written Directives for doses above 30 uCi of I-131

Effective today, all the written directives for all dosages greater than 30uCi of I-131 sodium iodide will be placed in a color coded form as it has been Beta Gamma standard operation for I-131 therapy doses for hyperthyroidism and thyroid cancer. This will ensure that the I-131 written directives are not misplaced and more readily accessible for any inspection of records.

Please keep this Memorandum posted at all times.